1. Home
  2. BW vs XERS Comparison

BW vs XERS Comparison

Compare BW & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$82.90

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$8.67

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BW
XERS
Founded
1867
2005
Country
United States
United States
Employees
N/A
435
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
BW
XERS
Price
$82.90
$8.67
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$8.00
$10.83
AVG Volume (30 Days)
4.8M
1.6M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
41.46
100.00
EPS
N/A
N/A
Revenue
$1,062,388,000.00
$49,590,000.00
Revenue This Year
$41.58
$34.37
Revenue Next Year
$66.70
$22.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
142.67
52 Week Low
$1.65
$5.25
52 Week High
$22.03
$10.08

Technical Indicators

Market Signals
Indicator
BW
XERS
Relative Strength Index (RSI) 36.98 57.71
Support Level $7.98 $6.97
Resistance Level $11.79 $9.01
Average True Range (ATR) 0.93 0.36
MACD 0.06 0.03
Stochastic Oscillator 7.32 83.76

Price Performance

Historical Comparison
BW
XERS

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: